Academics & Research

Immunology, Inflammation, & Infectious Disease (3i) Initiative

COVID-19 Funding Opportunities

Internal Funding Opportunity: 

The Immunology, Inflammation, and Infectious Disease (3i) Initiative in partnership with the Office of the Vice President For Research at the University of Utah is pleased to announce a request for proposals for research projects specifically focused on the COVID-19/SARS-CoV-2 virus and the related pandemic. The goal of this program is to support and enhance preliminary/project data for emerging research projects that will create competitive applications that are able to quickly respond to national funding opportunities.

Applications are due March 31st with decisions made by April 7th. The RFA can be accessed here.  


Other Funding & Award Opportunities

Funding opportunities are broken into two groups:

Click the Opportunity Number or Title to be redirected to the funding opportunity announcement.

Foundations and Other Organizations Funding Opportunities:

Foundation Grant Support: For assistance with strategic approaches to private foundations, faculty and staff are encouraged to reach out to Lynn Marsella Wong, Director of Foundation Relations, U Health (lynn.wong@hsc.utah.edu), or Chris Ostrander, Executive Director of Foundation Relations (chris.ostrander@utah.edu).

Organization

Title

Due Date

 Medical Technology Enterprise Consortium

 Request for Project Proposals

 

  • (RPP) for prototypes of medical and information technologies to combat Covid-19. Potential areas of interest:
    • Point-of-care diagnostic that provides rapid and accurate determination on exposure to COVID-19.
    • Prophylactic(s)/Therapeutic(s) that can prevent and/or treat in a rapid manner (few hours to 2 days) potentially
      in a non-hospital environment. Repurposing FDA-approved drugs/biologics for prevention/treatment of COVID-
      19 or testing of drugs/biologics that have already demonstrated safety in humans are preferred.
    • Disease predictive modeling that provides early warning through data capture from several different streams of
      data to include social media and artificial intelligence (AI) parameter decision tools that would provide
      actionable information to medical service providers and command structures.
    • Patient monitoring, tracking, and management system for in-home or non-hospital environment patient telehealth
      services to include interface into the Cerner electronic health record.” If the Army does release a formal
      solicitation, the RPP will be posted to the MTEC website, likely within the next few weeks.
Chan Zuckerberg Initiative (CZI) Chan Zuckerberg Initiative Coronavirus Response See website for various opportunities
Through our mission of supporting the science and technology that will make it possible to cure, prevent, or manage all diseases by the end of this century — we are already making an impact in helping scientists and researchers on the frontlines of this outbreak. The work of CZI’s team is aimed at leveraging open science, technology, and collaboration to accelerate our shared understanding of COVID-19. And in collaboration with our partners and across our network of grantees, CZI is helping fight this virus by increasing access to testing, genomic sequencing, research, community support, and more.
The Gates Foundation COVID-19 Opportunity: COVID-19 Therapeutics Accelerator (Application Details To Come)
The Bill & Melinda Gates Foundation, Wellcome and Mastercard today committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The partners are committed to equitable access, including making products available and affordable in low-resource settings. The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. Currently, there are no broad-spectrum antivirals or immunotherapies available for the fight against emerging pathogens, and none approved for use on COVID-19.
MIT Solve Health Security - New Solve Challenge

In the near term, we need improved solutions for prevention, accurate detection, and rapid response. MIT Solve is seeking tech innovations that can slow and track the spread of an emerging outbreak, for example by improving individual hygiene, developing low-cost rapid diagnostics, analyzing data that informs decision making, and providing tools that support and protect health workers.

At the same time, we cannot solely treat disease outbreaks reactively. Climate change and globalization leave us ever more vulnerable to future epidemics and pandemics, and it’s critical to be prepared. Solve is also seeking solutions that focus on preventative and mitigation measures that strengthen access to affordable primary healthcare systems, enhance disease surveillance systems, and improve healthcare supply chains.

We need your help:

  • If you have a solution, we want you to apply.

  • If you can help us fund a prize for the selected Solver teams, please get in touch with Hala Hanna at hala@solve.mit.edu.

  • You can also donate here—all amounts raised will support the Challenge.  

  • If you can partner with us in any other way, please let us know here

Medical CBRN Defense Consortium (MCDC)

Medical CBRN Defense Consortium (MCDC) Other Transaction Agreement (OTA) Request for Information (RFI) – CoV Pandemic Response

May 31, 2020

The purpose of this special notice is to obtain information via White Papers from both MCDC members and other interested industry/academia partners in response to the novel Coronavirus (2019-nCoV) pandemic in the United States (U.S.).  The Government is requesting White Papers with a focus on the following areas:

  • Diagnostics/Monitoring: Medical diagnostic devices, with specific emphasis on Point-of-Care diagnostics (e.g. CLIA waived), under development and capable of diagnosing 2019- SARS-CoV-2, and achieving Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) within the next one to four (1-4) months.
  • Surveillance: Surveillance methods and associated devices for 2019-SARS-CoV-2 screening. Any technology that can enhance the understanding of disease progression in COVID-19 infected patients is also of interest, including physiologic monitoring and other vital signs indicators, portable technology that enhances patient care in non-hospital settings, and technology that improves sample collection.

Note: Offerors can consider pursuing Assay and/or Device development efforts that could be used for health surveillance, medical diagnostics, or potentially both.  Medical diagnostics efforts need to ensure that they meet required regulatory pathways. 

  • Information systems and technology the Government can use in a handheld Point-of-Care device to collect, screen, collate, report, and monitor disease infection and pandemic spread on a micro and macro level.
  • Therapeutics: Drugs and/or drug/device combinations, or platforms currently under development demonstrating efficacy in post-exposure, pre- and post-symptomatic studies for any CoV strain, and capable of achieving EUA from the FDA within the next three (3) months for this ongoing SARS-CoV-2 pandemic. Antibody technologies, accelerating the discovery, development, manufacturing, and prediction of success for these technologies, can also be considered.
  • Prophylactics: Drugs or vaccines currently under development demonstrating pre-exposure in vivo efficacy or in vitro activity against any or all strains of CoV. Antibody technology, accelerating the discovery, development, manufacturing and prediction of success for these technologies can be considered.
  • Clinical Trials: Opportunities to expeditiously conduct clinical trials for any technology that will require evaluation for FDA approval, will be considered.

Novartis

Novartis COVID-19 Response Fund  Application Details To Come

Novartis today announced a broad set of measures to support the global response to the COVID-19 pandemic. These measures include the creation of a global fund to support communities around the world impacted by the COVID-19 pandemic as well as the company’s decision to join two key cross-industry R&D initiatives.

lifeArc

Coronavirus (COVID-19) Therapeutics: £10 Million Call For Rapid Deployment

Rolling

LifeArc has made available an initial £10M for the identification of therapeutics that can be rapidly deployed to treat COVID-19. The aim is to run trials in patients during the current epidemic. It is anticipated that applications will be for funding to repurpose one or more drugs that are generic, already licensed, or are in late stage development for another indication.

Federal Funding Opportunities

Agency Title Due Date
White House Office of Science and Technology Policy COVID-19 High Performance Computing (HPC) Consortium
This consortium is a unique private-public effort to bring together federal government, industry, and academic leaders to execute complex computational research programs. Researchers are invited to submit COVID-19 related research proposals to the consortium via this online portal, which will then be reviewed for matching with computing resources from one of the partner institutions. An expert panel comprised of top scientists and computing researchers will work with proposers to assess the public health benefit of the work, with emphasis on projects that can ensure rapid results.
XSEDE Website
National Science Foundation National Science Foundation/Rapid Response Research (RAPID)

NSF is accepting COVID-19 proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge. 

Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)
Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)


Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities. Such activities would be funded by the Computational and Data-Enabled Science and Engineering (CDS&E) program or the Cyberinfrastructure for Sustained Scientific Innovation (CSSI) program.


Proposals in response to this DCL and the NSF DCL on COVID-19 (NSF 20-052) may also request the use of NSF-funded advanced computing resources such as Frontera, Stampede2, Bridges, Comet, and JetStream.

Frequently Asked Questions for Proposers and Awardees

 Centers for Disease Control – OSTLTS

 Supplemental: Strengthening Public Health Systems and Services through National Partnerships to Improve and
Protect the Nation’s Health

 

Funding Opportunity Number: CDC-RFA-OT18-18020202SUPP20
CDC announces the availability of supplemental funding for the organizations that were previously awarded funding
under Funding Strategy 1 of CDC-RFA-OT18-1802: "Strengthening Public Health Systems and Services through National
Partnerships to Improve and Protect the Nation's Health" in FY18. 2) Organizations meeting this criteria are eligible to
apply for new CIO Project Plans specifically intended to address the current outbreak of COVID-19, and may apply
according to the Target Population Category (A,B, or C) and Target Population for which they received initial funding in
FY18.3) Link: grants.gov Search on funding number CDC-RFA-OT18-18020202SUPP20
Food and Drug Administration/Office of the Chief Scientist (OCS) and Center for Drug Evaluation and Research (CDER),
Office of Medical Policy (OMP)
Drug Development Science Support (U01)
Announces the intent to release a grant to protect and promote the health of the American public by creating new,
applied scientific knowledge, tools, standards and approaches to evaluate products more effectively, predictably and
efficiently. NOTE: This is a Forecasted Opportunity. Estimated start date: Sept 01, 2020.
HHS/Biomedical Advanced Research and Development Authority (BARDA)
Updated a broad agency announcement (BAA) to solicit proposals for advanced development and licensure of COVID-19
diagnostics, vaccines, or medicines such as therapeutics or antivirals. BARDA will provide funding, as well as expertise
and core services to support development projects selected through this BAA. These products include diagnostic tests
(assays); vaccines; therapeutics; medications to help regulate or normalize the immune system (immunomodulators);
therapeutics targeting lung repair; medicines that prevent infections either before or after exposure to the virus (preexposure
or post-exposure prophylaxis); respiratory protective devices; and ventilators. BAA-18-100-SOL-00003-
Amendment 13 (March 4, 2020)
HHS/Biomedical Advanced Research and Development Authority (BARDA)
BARDA opened an easy broad agency announcement, an EZ-BAA, seeking diagnostics that utilize platforms already
cleared by the FDA, with a viable plan to meet requirements for the FDA to consider emergency use authorization within
12 weeks.
HHS/Office of the Assistant Secretary for Preparedness and Response (ASPR) Public Health Emergency development of new medical countermeasures
Public Health Emergency development of new medical countermeasures
HHS/Centers for Disease Control and Prevention (CDC)
Funding to provide resources to state and local jurisdictions in the coronavirus disease 2019 (COVID-19) response. CDC is
contacting State Health Officers to move forward with awarding over $560 million to states, localities, territories, and
tribes. CDC will use existing networks to reach out to state and local jurisdictions to access this initial funding. Listing of
funding to jurisdictions here.
NIH/National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of General Medical Sciences
(NIGMS)
Notice of Special Interest (NOSI) Regarding the Availability of Urgent Competitive Revisions for Research on the 2019
Novel Coronavirus (2019-nCoV)
Notice Number: NOT-AI-20-030
NIAID and NIGMS are collaborating to highlight the urgent need for research on the 2019 novel Coronavirus (2019-
nCoV). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as
projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and
therapeutics against 2019-nCoV.
NIH/National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of General Medical Sciences
(NIGMS)
Administrative Supplementals
Current grantees may be eligible to apply for an administrative supplemental. Contact your program officer to discuss
proposed research on SARS-CoV-2/COVID-2019. If it is within the scope of your current grant, an administrative
supplement is the best option to obtain additional funding. PA-18-591
NIH/National Heart, Lung, and Blood Institute NHLBI is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease
2019 (COVID-19) and on biological effects of its causative agent, the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). Notice Number: NOT-HL-20-757
Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood (HLB) diseases,
potential impacts on transfusion safety, and clinical outcomes of infected individuals.
NIH/National Institute on Drug Abuse (NIDA) Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive
Revisions for Research on the 2019 Novel Coronavirus
Notice Number: NOT-DA-20-047
NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel
Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining
data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.
National Institute of Allergy and Infectious Diseases (NIAID) Coronavirus Resources for Researchers
Coronavirus Resources for Researchers
National Institutes of Health/Office of The Director
Given the fact that COVID-19 and associated impacts continue to evolve, applicants and recipients are strongly
encouraged to monitor NIH website for updates.
NIH/Fogarty International Center
Coronavirus news, funding and resources for global health researchers
World Health Organization
World scientists on COVID-19 met at the World Health Organization’s Geneva headquarters in February 2020 to assess
the current level of knowledge about the new virus, agree on critical research questions that need to be answered
urgently, and ways to work together to accelerate and fund priority research that can contribute to curtail this outbreak
and prepare for future outbreaks. R&D Blueprint
Department of Energy COVID-19 Rapid Research Response
DOE is soliciting ideas about how the Department and the National Laboratories might contribute resources for science
and technology efforts and collaborations. The Department is encouraging the scientific community and others to
consider research questions that underpin COVID-19 response and is requesting input on strategic, priority research
directions that may be undertaken using DOE user facilities, computational resources, and enabling infrastructure.
Dear Colleague
DOE Resources Supporting Coronavirus Research
Department of Defense Defense Logistics Agency (DLA) Troop Support Clothing & Textiles Directorate
Request for Information for PPE in response to COVID-19
Notice ID:SPE1C1-20-R-COVID19
DLA is conducting market research to determine industry capabilities for providing Personal Protective Equipment (PPE)
against viral contamination, specifically COVID-19. This is a Request for Information only and not a solicitation for award.
Defense/Army Medical Research Acquisition Activity (USAMRAA) USAMRAA’s COVID-19 FAQs
This notice addresses general questions associated with proposal submission and award management that may arise
in relation to COVID-19. These FAQs will be updated here as more information becomes available
Department of Homeland Security TSA Industry Assistance with COVID-19
Notice ID: 2020-TSA-IndustryNotice
In the current climate TSA appreciates industry offering to assist the Agency in response to COVID-19. Please submit
your offering to the Contracting and Procurement office point of contact, Evelyn S. Tyndell at
EngageProcurement@tsa.dhs.gov to ensure appropriate handling.
DOJ/Office of Community Oriented Policing Services Office (COPS)
COPS has extended the solicitation deadline for several open grant programs due to the potential impact of jurisdictional
emergency responses to COVID-19 that may cause reasonable delays for applicants. For detailed individual program
information, see the grants page.
DOJ/Office of Justice Programs
OJP announced that solicitations with application due dates before April 1st will have a 2 week extension for
submission. OJP Grantee Update #1 COVID-19 Impacts
CDC 

Centers for Disease Control COVID-19 Broad Agency Announcement

March 25th, 2020
The Centers for Disease Control and Prevention is issuing Broad Agency Announcement (BAA) number 75D301-20-R-67897. The NAICS code for this BAA is 541705, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology and Nanotechnology) with a size standard of 1,000 employees. This BAA is open and in effect for 14 days from the date of issuance (March 11, 2020 through March 25, 2020). THIS IS AN IMMEDIATE CALL FOR WHITE PAPERS. Prior to submission of a white paper, offerors are strongly encouraged to contact the CDC BAA technical point of contact for the research topic/subtopic of interest. White papers must be received electronically by 3:00PM EST on March 25, 2020 in order to be considered for further evaluation. White papers should be submitted electronically to Jan Gum at tzg7@cdc.gov.
NIH/NIAID

2020 NIAID Omnibus Broad Agency Announcement

Various Dates (See Call)

NIAID 2020 OMINBUS BROAD AGENCY ANNOUNCEMENT (BAA) NO. HHS-NIH-NIAID-BAA2020-1 contains five (5) distinct Research Areas, each with a specified closing date and time. The proposal due date of February 28, 2020, specified in this solicitation posting, is the due date for Research Area 002 only. An Amendment will be issued at a later date to update the proposal due date for responses to Research Area 001, 003, 004, and 005.  The proposal due dates for each Research Area are identified below:

DAIT: Research Area 001 - Development of Radiation/Nuclear Medical Countermeasures (MCMs)

Proposals Due Date and Time: 3:00 PM Eastern Time, 04/09/2020

DMID: Research Area 002 - Advanced Development of Vaccine Candidates for Acute Flaccid Myelitis Associated with Enterovirus D68

Proposals Due Date and Time: 3:00 PM Eastern Time, 02/28/2020

DMID: Research Area 003 - Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases

Proposals Due Date and Time: 3:00 PM Eastern Time, 04/09/2020

DMID: Research Area 004 - Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases

Proposals Due Date and Time: 3:00 PM Eastern Time, 04/09/2020

DMID: Research Area 005 - Advanced Development of Diagnostics for Biothreats and Emerging Infectious Diseases

Proposals Due Date and Time: 3:00 PM Eastern Time, 04/09/2020

National Institute of Allergy and Infectious Diseases (NIAID)

Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed) June 29th, 2020

The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms (R21 Clinical Trial Not Allowed) September 9th, 2020

The purpose of this Funding Opportunity Announcement (FOA) is to support the use of Collaborative Cross (CC) mouse lines to advance understanding of the host genetics involved in immune regulation and function and to further develop CC mouse lines that more faithfully reproduce human immune responses. Applicants may include CC, CC derivatives with reproducible genomes and/or CC-RIX mice to accomplish these goals. Research areas supported by this FOA include immune system development, function or regulation; mechanisms governing immune response to infectious pathogens, vaccines or adjuvants; host susceptibility factors and mechanisms of pathogen-induced immunopathology; and immune mechanisms involved in the development and progression of immune-mediated diseases, such as allergy/asthma, autoimmunity, primary immunodeficiency, inflammation, and cell/organ/tissue transplant rejection or tolerance.

National Institute on Aging (NIA)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)
National Institute of Environmental Health Sciences (NIEHS)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute of Biomedical Imaging and Bioengineering ( NIBIB )

Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement -  Clinical Trial Optional) Various Dates

The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted.  Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award.

Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA.  

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute on Aging (NIA)

Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) May 13, 2020; September 13, 2020; January 13, 2021; May 13, 2021; September 13, 2021; January 13, 2022; May 13, 2022; September 13, 2022; January 13, 2023
This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of one of the participating ICs. Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application. This FOA is not intended for support of clinical trials that do not require an extended project period of 6 or 7 years.